Vitesse Gains Speed With First Venture, Built On Astellas Asset
This article was originally published in PharmAsia News
Executive Summary
Astellas is continuing to divest non-core pipeline assets, this time a candidate for B-cell disorders including lupus, which will be the basis of the first venture to be formed by Baxalta-affiliated Vitesse Biologics.